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Summary
Objective: In the present study, we sought to develop/characterize the pain proﬁle of a rat model of surgically induced osteoarthritis (OA).
Methods: OA was surgically induced in male Lewis rats (200e225 g) by transection of the medial collateral ligament and medial meniscus of
the femoro-tibial joint. In order to characterize the pain proﬁle, animals were assessed for a change in hind paw weight distribution (HPWD),
development of mechanical allodynia, and the presence of thermal and mechanical hyperalgesia. Rofecoxib and gabapentin were examined
for their ability to decrease change in weight distribution and tactile allodynia.
Results: Transection of the medial collateral ligament and medial meniscus of male Lewis rats resulted in rapid (<3 days) changes in hind paw
weight bearing and the development of tactile allodynia (secondary hyperalgesia). There was, however, no appreciable effect on thermal
hyperalgesia or mechanical hyperalgesia. Treatment with a single dose of rofecoxib (10 mg/kg, PO, day 21 post surgery) or gabapentin
(100 mg/kg, PO, day 21 post surgery) signiﬁcantly attenuated the change in HPWD, however, only gabapentin signiﬁcantly decreased tactile
allodynia.
Conclusion: The rat medial meniscal tear (MMT) model mimics both nociceptive and neuropathic OA pain and is responsive to both a selective
cylooxygenase-2 (COX-2) inhibitor commonly utilized for OA pain (rofecoxib) and a widely prescribed drug for neuropathic pain (gabapentin).
The rat MMT model may therefore represent a predictive tool for the development of pharmacologic interventions for the treatment of the
symptoms associated with OA.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common form of joint disease
with over one-half of all people older than age 65 demon-
strating radiographic changes of OA in the knees1. OA is
primarily noted in the weight-bearing joints (i.e., knees,
hips) and is associated with degeneration of the articular
cartilage and changes to the subchondral bone at the joint
margins2. Clinically, OA manifests itself as joint pain with
concomitant loss of joint function, which may ultimately
result in a substantially reduced quality of life for the patient.
While a great deal is known about the symptomatic aspects
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Received 29 August 2005; revision accepted 1 May 2006.10of the disease, the pathophysiology behind the aforemen-
tioned structural changes is complex and poorly understood.
Currently, there are no commercially available pharmaco-
logic approaches deﬁnitively proven clinically to alter the
natural progression of this disease. The supplements, glu-
cosamine and chondroitin sulfate, however, may have the
ability to provide chondroprotective effects and improve
some of the signs and symptoms associated with OA3,4.
In the absence of disease modifying drugs, the treatment
of patients with OA is often directed at relieving pain and
restoring function through the use of pharmacologic therapi-
es5e7. Nonsteroidal anti-inﬂammatory drugs (NSAIDs) and
selective cylooxygenase-2 (COX-2) inhibitors are widely
prescribed for the treatment of OA pain. These drugs
have a number of issues, however, including potential
undesirable side effects and variable efﬁcacy. Therefore,
the need remains for new pharmacologic approaches for
the treatment of OA pain either as stand-alone or add-on
therapy with existing drugs.41
1042 S. E. Bove et al.: MMT-induced OA-like joint painWhile the pain associated with OA is primarily localized to
the joint, it is becoming increasingly apparent that a number
of patients exhibit increased nociception to adjacent or even
remote areas of the body8e10. For example, Kosek and
Ordeberg8 found that patients with unilateral hip OA had
decreased pain thresholds in the normal, contralateral hip,
while DeBerry and coworkers10 showed that patients with
knee OA demonstrated increased sensitivity to pressure
pain in the hip as compared to healthy, age-matched
controls. This phenomenon, referred to as secondary
hyperalgesia or allodynia, is thought to be the result of cen-
tral sensitization11e13. For this reason, it is now becoming
common for OA to be thought of, in part, as a neurological
disease with central input in addition to the pain originating
at the affected joint. Pain inhibitors that target both joint
pain and secondary hyperalgesia/allodynia may therefore
represent the optimal approach for reducing OA pain. As
such, there exists a need for in vivo models that accurately
mimic both the pathologic changes and pain proﬁle (central
and peripheral components) that are noted in human OA.
We report here the characterization of a surgically induced
rat model of OA pain that possesses both primary joint pain
with concurrent secondary hyperalgesia. This model may,
therefore, represent an ideal platform by which to study
the nociceptive responses associated with the disease as
well as be of use in the development of new pharmacologic
agents for the treatment of OA symptoms.
Methods
All procedures used in this study were approved by, and
in accordance with, the guidelines of the Pﬁzer Animal Care
and Use Committee. Animal facilities are accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care, International. Rats were kept in a 12:12 h
lightedark cycle and housed in solid bottom cages with
corncob bedding for the duration of the study, except where
otherwise noted. Rats were fed standard rat chow with
water available ad libitum.
INDUCTION OF OA
Adult male Lewis rats (Charles River, Wilmington, MA)
weighing 200e225 g were allowed to acclimate for 1
week prior to surgery. OA was surgically induced as de-
scribed previously14. Brieﬂy, animals were anesthetized
with isoﬂurane and the skin over the medial aspect of
the right femoro-tibial joint clipped to remove the hair
and surgically prepped with Nolvasan Surgical Scrub
(Fort Dodge Animal Health, Overland Park, KS) followed
by 70% alcohol. The medial collateral ligament (MCL)
was exposed by blunt dissection and transected to reﬂect
the meniscus toward the femur. The joint space was visu-
alized and the meniscus was cut through the full thickness
at its narrowest point to simulate a complete tear. The skin
was closed with 4.0 silk suture. For sham animals, the
medial collateral ligament was exposed, but not trans-
ected. An additional group of animals, referred to as
MCL sham rats, had their medial collateral ligament trans-
ected and the joint space visualized, but the meniscus
was not cut. These animals served as a control for the
transection of the ligament and its effect on change in
hind paw weight distribution (HPWD). All surgical sites
were observed daily for signs of abnormal healing
including, but not limited to swelling, redness, drainage,
bleeding and dehiscence.ASSESSMENT OF CHANGE IN HPWD
The change in HPWD was utilized as an index of joint
discomfort and was determined as described previously15.
Brieﬂy, changes in HPWD between the right (arthritic) and
left (contralateral control) limbs were utilized as an index
of joint pain in the surgically induced arthritic knee. An inca-
pacitance tester (Linton Instrumentation, Norfolk, UK) was
employed for the determination of HPWD. Rats (n¼ 8 per
group) were placed in an angled Plexiglass chamber posi-
tioned so that each hind paw rested on a separate force
plate. The force exerted by each hind limb (measured in
grams) is averaged over a 5-s period. Each data point is
the mean of three, 5-s readings. The change in HPWD
was calculated by determining the difference in the amount
of weight (g) between the left and right hind limbs. Three
separate studies (72 total animals) were conducted with
the data presented as the difference in weight bearing be-
tween the left (contralateral control) limb and right (arthritic)
limb.
MECHANICAL ALLODYNIA
Rats (64 total animals) were housed in wire-bottom
cages for the duration of the study. To assess mechanical
allodynia, animals were placed in suspended wire-bottom
cages and allowed to acclimate in a quiet, subdued light
environment for 30 min. The mechanical withdrawal
threshold of the hind paw was tested using a set of von
Frey monoﬁlament hairs (VFH). The VFH were applied
to bending at the center plantar region of the ipsilateral
hind paw, and the paw withdrawal threshold (PWT) was
determined using the Dixon Up-Down method16. Brieﬂy,
six VFHs with bending forces of 2.0e28.8 g were applied
for up to 6 s, beginning with the lowest force. If the rat did
not withdraw its paw (ﬂinch) in response to the force of
the VFH, the next higher force was applied, etc., until re-
coil was observed (deﬁned as the preliminary threshold).
As a result of the ﬂinch, the next lower VFH was then
employed. Up-down force application continued for four
applications post-preliminary threshold. The series of
ﬂinch/no-ﬂinch responses were used to calculate the ac-
tual PWT. If there was no response at 28.8 g, that force
was assigned.
THERMAL HYPERALGESIA
Thermal hyperalgesia was evaluated by the paw
withdrawal test17 using a Hargreaves apparatus (San
Diego, CA). The device consists of a glass surface upon
which the rats were placed individually in Plexiglass cubi-
cles. The glass surface temperature is maintained at 30(C
by a feedback-controlled, under-glass, forced-air heating
system. The animals were allowed to acclimate to their
surroundings for 15 min. Following acclimation, a 50-W
halogen light was positioned at the plantar surface of the
ipsilateral paw. When the pain threshold is achieved, the
animal ﬂinches its paw, stopping the illumination and
the timer. A cut-off time of 20-s is employed to avoid tis-
sue injury. The time from the onset of the heat application
to paw lifting is considered to be the paw withdrawal
latency (PWL). This is then recorded and read again
5 min later so as not to produce a summation of tissue
temperature. The average of the two readings is consid-
ered to be the PWL for that animal. Two separate studies
were conducted with eight animals per group (32 total
animals).
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Mechanical hyperalgesia was evaluated by the Randal-
leSelitto test18 using a paw pressure analgesia instrument
(Stoelting, Wood Dale, IL). The paw pressure pain threshold
was determined by placing the ipsilateral hind paw between
a ﬂat surface and a blunt pointer and applying steadily
increasing pressure (15 g/s). The threshold was determined
when the rat exhibited a stereotyped ﬂinch response and
attempted to remove the foot from the apparatus. If there
was no response at the maximum pressure (238.9 g), that
force was assigned. Two separate studies were conducted
with eight animals per group (32 total animals).
HISTOLOGIC ANALYSIS
Histologic changes were assessed in sham, MCL sham
and medial meniscal tear (MMT) rats 21 days post surgery.
Rats were euthanized by CO2 and soft tissue was removed
from the right (MMT, sham or MCL sham operated) leg. The
patella was removed from each knee to facilitate thorough
ﬁxation of the joint. Tissue samples were prepared for light
microscopy using standard procedures. Brieﬂy, samples
were preserved in 10% neutral-buffered formalin (VWR,
So. Plainﬁeld, NJ), and subsequently decalciﬁed in 5% for-
mic acid for 72 h. Samples were dehydrated in an ethanol
series and embedded in parafﬁn. Sections were stained
with toluidine blue according to previously published
methods19. Two separate studies were conducted with
three sham and six MMT-operated rats per group and one
study with three MCL sham rats (21 total animals).
Articular cartilage damage was assessed by examining
the degree of chondrophyte/osteophyte formation and carti-
lage loss or erosion. Subchondral bone damage was indi-
cated by subchondral sclerosis, bone marrow ﬁbrosis and
loss of bone marrow spaces. Inﬂammation was character-
ized by expansion of the synovial membrane by proteina-
ceous edema ﬂuid and ﬁbrin with inﬁltrating macrophages,
neutrophils, plasma cells and lymphocytes. All samples
were scored by a Board-certiﬁed veterinary pathologist (RG).
PHARMACOLOGIC CHARACTERIZATION
Rofecoxib (Merk & Co., Inc., Whitehouse Station, NJ;
n¼ 6 per group) was pulverized and suspended in hydrox-
ypropylmethylcellulose (HPMC; SigmaeAldrich, St. Louis,
MO) vehicle (0.5% HPMCþ 0.2% Tween 80). Gabapentin
(Pﬁzer, Inc., Ann Arbor, MI; n¼ 6 per group) was also sus-
pended in HPMC vehicle. A separate vehicle group (n¼ 8)
in which rats were dosed with HPMC vehicle alone was run
in conjunction with the drug-treated groups. Twenty-one
days post surgery, changes in HPWD or mechanical allody-
nia were determined, as described above, to establish
a baseline pain reading. The rats were then given a single
dose (oral gavage) of vehicle, rofecoxib (10 mg/kg), or ga-
bapentin (100 mg/kg). Changes in HPWD and mechanical
allodynia were determined 2 h post-compound administra-
tion. The data obtained are representative of three separate
studies for HPWD (eight animals per group, 72 total ani-
mals) and two separate studies for mechanical allodynia
(eight each for sham and vehicle and six each for gabapen-
tin and rofecoxib, 56 total animals).
STATISTICAL METHODS
All data are expressed as mean S.E.M. All statistical
tests were tested at the 0.05 level of statistical signiﬁcance.Time course data, post surgery, were analyzed by a
repeated measures analysis of variance (RMANOVA) with
terms for treatment, time, and the joint effect of treatment
and time (interaction). If the treatment by time interaction
was not statistically signiﬁcant, the mean responses of all
groups were compared in a pair-wise fashion, averaged
over time, via a TukeyeKramer multiple comparison proce-
dure adjustment. If the treatment by time interaction was
statistically signiﬁcant, the effect of differing interventions
could not be addressed without considering the time of
the measurement; groups were then compared in a cross-
sectional fashion (at each time point). A one-way analysis
of variance (ANOVA) followed by Dunnett’s multiple com-
parison’s procedure was performed on studies examining
the efﬁcacy of rofecoxib and gabapentin on change in
HPWD and mechanical allodynia.
Results
EFFECT OF MMT SURGERY ON CHANGE IN HPWD
As early as 3 days post surgery, MMT-operated rats
exhibited a signiﬁcant change in HPWD when compared
to sham and MCL sham-operated rats (Fig. 1). A maximal
level of change in HPWD was reached 3 days post surgery
and remained consistent through day 21. There was a slight
increase in change in HPWD in sham and MCL sham-
operated animals when compared to pre-surgery assess-
ments; however, this increase was not statistically
signiﬁcant. In addition, when sham rats were compared to
MCL sham rats, no signiﬁcant differences were found
between the two groups.
EFFECT OF MMT SURGERY ON MECHANICAL ALLODYNIA
Mechanical allodynia was assessed on the same groups
of rats 1 day before surgery (day 1) and again 3, 7, 14,
and 21 days post MMT or sham surgery [Fig. 2(A)]. It should
be noted that only a subset of MMT-operated rats devel-
oped hypersensitivity to punctate VFH stimulation on the
ipsilateral hind paw. The percentage of rats that did develop
Fig. 1. Effect of MMT surgery on change in HPWD. Change in
HPWD was assessed by use of an incapacitance tester 1 day
before and 3, 7, 14 and 21 days post MMT, sham or MCL sham
surgery. Statistically signiﬁcant differences were determined by
RMANOVA (*P< 0.0001) vs sham-operated rats. N¼ 8 rats per
group. Representative of three separate experiments.
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as a PWT of less than 16 g) increased as a function of time
with approximately 50% of rats exhibiting hypersensitivity
3 days post surgery and 70% by day 21 post surgery
[Fig. 2(B); N¼ 16 rats per group; combination of two sepa-
rate experiments]. This trend continued through day 28 post
surgery (87%; data not shown). There was no decrease in
PWT in sham-operated rats compared to pre-surgery
assessment.
EFFECT OF MMT SURGERY ON THERMAL AND MECHANICAL
HYPERALGESIA
Thermal (Fig. 3) and mechanical (Fig. 4) hyperalgesia
were assessed 1 day before surgery (day 1) and again
3, 7, 14 and 21 days post MMT or sham surgery. Neither
MMT nor sham surgery induced thermal or mechanical
hyperalgesia when compared to pre-surgery assessments.
Fig. 2. Effect of MMT surgery on mechanical (punctate) allodynia.
A. Mechanical allodynia was assessed using von Frey monoﬁla-
ments and expressed as PWT (in grams). PWT was determined
1 day before and 3, 7, 14 and 21 days post MMT or sham surgery.
Statistically signiﬁcant differences were determined by RMANOVA
(*P< 0.001) vs sham-operated rats. B. Percent of MMT rats exhib-
iting allodynia was calculated as follows: % incidence of rats exhib-
iting allodynia¼ ((# of rats with PWT <16 g)/(# of rats with PWT
16 g)) 100. N¼ 16 rats per group. Combination of two separate
experiments.MMT-INDUCED HISTOLOGIC CHANGES
Figure 5(A and B) represents sham and MCL sham con-
trol knees 21 days post surgery, respectively, with intact,
healthy cartilage and no loss of chondrocytes or proteogly-
can. No changes were noted to the subchondral bone or
synovium.
Rats sacriﬁced 21 days post MMT surgery [Fig. 5(C)] had
prominent osteophyte/chondrophytes in the medial tibial
plateau immediately adjacent to the area of cartilage ero-
sion or loss. Focally extensive areas of full thickness carti-
lage damage characterized by complete loss of cellular
detail and some loss of proteoglycan matrix, as determined
by Toluidine Blue staining, was also noted. There were
extensive areas of subchondral sclerosis in the medial tibial
plateau, which had markedly reduced and in some cases
Fig. 3. Effect of MMT surgery on thermal hyperalgesia. Thermal
hyperalgesia was assessed by use of a Hargreaves apparatus
and expressed as PWL (in seconds). PWL was determined 1 day
before and 3, 7, 14 and 21 days post MMT or sham surgery.
N¼ 8 rats per group. Representative of two separate experiments.
Fig. 4. Effect of MMT surgery on mechanical (blunt pressure) hyper-
algesia. Mechanical hyperalgesia was evaluated by the Randalle
Selitto test using a paw pressure analgesia instrument and ex-
pressed as the amount of force (g) necessary to elicit a stereotyped
ﬂinch response. Mechanical hyperalgesia was determined 1 day
before and 3, 7, 14 and 21 days post MMT or sham surgery.
N¼ 8 rats per group. Representative of two separate experiments.
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days post surgery. Frontal sections of the medial aspect of rat
knee joints were stained with Toluidine Blue. (A and B) Sham
and MCL sham surgery. Knees have normal healthy cartilage,
subchondral bone and synovium. (C) MMT surgery. Prominent
chondrophyte/osteophyte present adjacent to severe cartilage
erosion. Chondrocyte loss is complete to the deep zone and
signiﬁcant proteoglycan loss can be detected all the way to the
tidemark. Extensive subchondral sclerosis and bone marrow
ﬁbrosis is present with loss of some bone marrow spaces. No
synovial inﬂammation is present. Magniﬁcation 5. Representa-
tive of two separate experiments (n¼ 3e6 rats per group).obliterated the inter-trabecular bone marrow spaces.
Loosely arranged ﬁbrous tissue or clusters of osteoblasts
typically occupied remaining spaces.
EFFECT OF GABAPENTIN AND ROFECOXIB ON HPWD
AND MECHANICAL ALLODYNIA
Experiments designed to test the effect of gabapentin and
rofecoxib on change in HPWD and mechanical allodynia
were conducted on day 21 post surgery. Gabapentin
(100 mg/kg) and rofecoxib (10 mg/kg) signiﬁcantly
decreased change in HPWD 2 h post dose (Fig. 6; 45%
and 66% decrease, respectively). A subset of allodynic
rats was used to test the effect of gabapentin and rofecoxib
on the mechanical allodynia. Gabapentin, but not rofecoxib,
signiﬁcantly increased PWT (decreased mechanical allody-
nia) 2 h post dose (Fig. 7; 70% and 25% inhibition of
allodynia, respectively). No changes in behavior (i.e.,
drowsiness or agitation) were noted with either drug.
Discussion
Surgical transection of the anterior cruciate ligament
(ACL), meniscectomy, or resection of the tibial plateau in
experimental models has been shown to produce structural
changes including cartilage lesions and changes to the sub-
chondral bone associated with OA20e22. While these animal
models largely mimic the structural changes noted in
human OA, they have not been shown to simulate the
symptomatic aspects of the disease. In the absence of
pharmacologic interventions to treat the structural changes
associated with OA, ﬁnding novel compounds to treat the
symptoms of the disease takes on ever increasing impor-
tance. In the present study, we have sought to characterize
a rat model of joint pain based on surgical transection of the
medial collateral ligament and medial meniscus.
Fig. 6. Effect of rofecoxib and gabapentin on change in HPWD.
MMT surgery was performed on day 0. On day 21 the rats were
assessed on an incapacitance tester for change in HPWD to estab-
lish pre-dose values. Rats were then administered 10 mg/kg rofe-
coxib, 100 mg/kg gabapentin, or vehicle (PO) and reassessed 2 h
later. Statistically signiﬁcant differences were determined using
one-way ANOVA followed by Dunnett’s multiple comparison’s
procedure (*P< 0.05 vs vehicle at the same time point). N¼ 8
rats per group. Representative of three separate experiments.
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previously demonstrated by Bendele14 to result in the rapid
(<3 weeks) degeneration of cartilage. Histologically, the ini-
tial damage to the cartilage, as deﬁned by ﬁbrillation and
loss of proteoglycan, is localized to the medial side. In the
latter stages, there is signiﬁcant cartilage damage and, in
some cases, complete loss of the cartilage layer with sub-
sequent exposure of the subchondral bone. Large medial
tibial plateau osteophytes are also present by 3 weeks
post surgery (Fig. 5). Alterations to the subchondral bone
may be noted at approximately 7 days post surgery and
continue throughout the duration of the model. The similar-
ity of the lesions seen in the rat MMT model to those noted
in the human condition provide the rationale for examining
the behavioral responses in the rat following transection
of the medial meniscus. These histologic similarities,
coupled with the ability of commonly utilized therapeutic
analgesics to inhibit changes in HPWD and mechanical al-
lodynia (secondary hyperalgesia/allodynia), suggest that
the rat MMT model has potential value for use in the identi-
ﬁcation of novel approaches designed to decrease the clin-
ical symptoms associated with OA, as well as identifying
targets to alter the associated structural changes to the car-
tilage and bone.
Change in HPWD was utilized as the primary index of
joint pain in the present study. We and other investigators
have previously demonstrated that this approach offers a di-
rect, rapid method by which to test the ability to bear weight
in a deﬁned joint15,23,24. Transection of the medial collateral
ligament and medial meniscus resulted in a time-dependent
increase in the weight-bearing differential between the
arthritic knee and the contralateral control knee (Fig. 1).
The increased change in HPWD continued throughout the
duration of the 3-week protocol which, coupled with histo-
logic changes, is indicative of a chronic OA-like pain. It
should be noted that sham-operated animals also demon-
strated a slight increase in HPWD on days 3 and 7 post sur-
gery, although to a much lesser degree than that noted for
Fig. 7. Effect of rofecoxib and gabapentin on mechanical (punctate)
allodynia. MMT or sham surgery was performed on day 0. On day
21, PWT was determined. The rats were then administered 10 mg/
kg rofecoxib, 100 mg/kg gabapentin, or vehicle (PO) and reas-
sessed 2 h later. Statistically signiﬁcant differences were deter-
mined using one-way ANOVA followed by Dunnett’s multiple
comparison’s procedure (*P< 0.05 vs vehicle). N¼ 8 (vehicle and
sham) or six (rofecoxib and gabapentin) rats per group. Represen-
tative of two separate experiments.arthritic animals. These changes, however, were not signif-
icantly different from pre-surgery measurements and it is
hypothesized that the alterations in weight distribution in
sham-operated animals may be due to the effects of the
surgery and a subsequent inﬂammatory response at the
surgical site. Inﬂammatory cells, including neutrophils and
monocytes, have been shown to possess the capacity to
release a number of soluble mediators that can directly
stimulate primary afferent neurons. Histologic analysis of
both the arthritic and contralateral control joints showed
that, at 3 days post surgery, there is a degree of inﬂamma-
tion present, composed primarily of granulation tissue and
ﬁbrosis with few mononuclear cell inﬁltrates (data not
shown). These histologic changes were noted in both
arthritic and sham-operated control joints and are likely as-
sociated with resolution of the surgical incision. The inﬂam-
matory response, as characterized by the lack of any cell
inﬁltrate, had largely resolved by 7 days post surgery.
MCL sham rats also exhibited a small increase in HPWD
3 days post surgery, which remained slightly elevated
through day 21 and was not signiﬁcantly different from
sham rats. This increase may be due in part to a slight de-
stabilization of the joint resulting from the MCL transection.
Recently, Fernihough et al.25 described a model of surgi-
cally induced OA pain generated by transection of the
meniscus while sparing the medial collateral ligament. In
contrast to our ﬁndings, Fernihough et al.25 did not demon-
strate an appreciable difference in HPWD with their menis-
cal tear model. The possibility exists that transection of the
medial collateral ligament, as was done in our studies,
directly results in loss of joint stability and a subsequent
change in HPWD. To address this question, we conducted
a number of studies to directly examine the effect of medial
collateral ligament transection on HPWD. It was found that
transection of the ligament, in the absence of alterations to
the meniscus (MCL sham), did not signiﬁcantly alter HPWD
as compared to sham animals (Fig. 1). It is also possible
that in order to elicit a signiﬁcant change in HPWD both
the medial collateral ligament and meniscus need to be
transected as was done in this study. Further, it is feasible
that strain and/or gender differences may play a role in the
divergence of HPWD results. A number of previous studies
have demonstrated gender and strain-dependent differ-
ences in nociceptive sensitivity26e28. Both studies utilized
male rats, however, our study used the Lewis strain while
Fernihough et al.25 used Wistar rats. Lewis rats have a
defective HPA axis, which could potentially lead to
increased pain compared to Wistar rats due to decreased
levels of circulating glucocorticoids29.
OA pain is of multifactorial origin, and is now thought to
be composed of both peripheral and central nervous system
components. While the pain that is associated with OA is
primarily localized to the joint, it is becoming increasingly
apparent that a number of patients exhibit increased noci-
ception to adjacent or even remote areas of the body8e10.
This secondary hyperalgesia/allodynia is primarily the result
of central sensitization11e13. The increase in afferent signal-
ing from the joint nociceptors to the spinal cord neurons
results in increased sensitivity of the spinal cord neurons to
input from the joint, rendering the spinal cord neurons
hyperexcitable. Secondary hyperalgesia/allodynia occurs
when the sensitized spinal cord neurons exhibit enhanced
responses to stimuli from non-injured areas of the leg30.
While weight bearing is a suitable behavioral determinant
for joint pain, it does not measure all aspects of pain that
can be associated with OA, such as secondary hyperalge-
sia/allodynia. We therefore decided to characterize the rat
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order to determine if a secondary hyperalgesia/allodynia
component was present in this model. While multiple types
of mechanical hyperalgesia/allodynia exist, only two types
are associated with secondary hyperalgesia/allodynia:
punctate hyperalgesia (mechanical allodynia; von Frey
monoﬁlament test) and stroking hyperalgesia (cotton swab
test)31e33. In this study we tested punctuate hyperalgesia
(von Frey monoﬁlament test).
The von Frey monoﬁlament test was used to examine the
MMT model for a secondary allodynia component. Mechan-
ical allodynia was assessed in the plantar region of the
ipsilateral hind paw of MMT-operated rats using VFH mono-
ﬁlaments [Fig. 2(A)]. It is interesting to note that, similar to
the human condition, not all of the MMT-operated rats
exhibited secondary hyperalgesia [Fig. 2(B)]. The incidence
of allodynic response in the MMT rats increased as a func-
tion of time, with 70e80% of the rats exhibiting secondary
allodynia by 14e21 days post surgery. According to several
studies conducted in which OA patients were evaluated for
secondary hyperalgesia/allodynia, only a subset of patients
experienced decreased pain thresholds away from the ini-
tial location of the joint pain8,9,10,34. Histologic analysis did
not reveal appreciable differences in the cartilage, subchon-
dral bone or the degree of synovial inﬂammation between
those animals that exhibited secondary hyperalgesia vs
those that did not. The results suggest that another under-
lying pathophysiologic mechanism is responsible for the
presence/absence of secondary hyperalgesia.
Two additional tests were employed to examine referred
pain in the ipsilateral hind paw. These tests were for thermal
hyperalgesia and blunt pressure mechanical hyperalgesia.
Thermal hyperalgesia was not present in any of the MMT
or sham-operated rats (Fig. 3). This observation concurs
with previously published literature in which secondary
hyperalgesia was evaluated after capsaicin injury35 or
heat injury36,37 to skin. In these studies it was concluded
that secondary hyperalgesia is characterized by hyperalge-
sia to mechanical, but not heat stimuli. Similar ﬁndings in
human patients have been observed by Bradley et al.10
demonstrating that there was no measurable difference be-
tween OA patients and control subjects to heat stimulation
at the same sites. Interestingly, MMT-operated rats did
not exhibit blunt pressure (RandalleSelitto test) mechanical
hyperalgesia either (Fig. 4). Our ﬁndings are in accord with
Fernihough et al.25 in which blunt pressure mechanical
hyperalgesia was not observed in their model of surgical
meniscal tear in rats. These observations are also consis-
tent with a separate study in human hairy skin by Koltzen-
burg et al.38 suggesting that blunt pressure hyperalgesia
is not present in the zone of secondary hyperalgesia.
In order to pharmacologically validate this model, groups
of animals were treated with the COX-2 speciﬁc inhibitor, ro-
fecoxib, or the novel anticonvulsant drug, gabapentin, which
has been shown to effectively reduce neuropathic pain in
several animal models39e42. Oral administration of these
compounds signiﬁcantly attenuated the change in HPWD
in a manner consistent with the expected time course and
dose of the compound (Fig. 6). The positive responses
noted with these analgesics indicate that the model re-
sponds favorably to pharmacologic intervention in a manner
similar to that seen in the human. Further, these data also
provide evidence that the changes in HPWD are not due ex-
clusively to destabilization of the knee joint since one would
not expect these agents to reverse destabilization-induced
changes in weight distribution. In a subset of animals that
were exhibiting secondary hyperalgesia, as assessed byVFH monoﬁlaments, only gabapentin was able to alleviate
mechanical allodynia (Fig. 7). It is not unexpected that a sin-
gle, orally administered dose of rofecoxib did not effectively
inhibit secondary allodynia as COX-2 inhibitors are consid-
ered to be generally ineffective when it comes to relieving
neuropathic or centrally-mediated pain43. It is possible to al-
leviate neuropathic pain and central sensitization with
a COX-2 inhibitor, but usually only by local administration
or chronic administration over a period of several days44e46.
These data suggest that the rat MMT model may have
predictive value for evaluating novel pharmacologic
approaches for the treatment of OA pain characterized by
both primary and secondary hyperalgesia.
In summary, the MMT model of joint pain is a surgically
induced model that effectively mimics both the structural
and symptomatic changes associated with human OA.
This close association, both morphologically and symptom-
atically, to the human condition, coupled with the ability of
the model to respond to conventional pain-relieving thera-
pies, indicates that the MMT model may be useful for the
development of pharmacologic interventions for the treat-
ment of the symptoms associated with OA. Additionally,
the availability of such models that closely mimic the dis-
ease may provide important information as to the molecular
mechanisms involved in the genesis of OA pain.
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